These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9160113)

  • 1. Sodium channels and therapy of central nervous system diseases.
    Taylor CP; Narasimhan LS
    Adv Pharmacol; 1997; 39():47-98. PubMed ID: 9160113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs.
    Catterall WA
    Adv Neurol; 1999; 79():441-56. PubMed ID: 10514834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four novel tarantula toxins as selective modulators of voltage-gated sodium channel subtypes.
    Bosmans F; Rash L; Zhu S; Diochot S; Lazdunski M; Escoubas P; Tytgat J
    Mol Pharmacol; 2006 Feb; 69(2):419-29. PubMed ID: 16267209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Traditional AMPA receptor antagonists partially block Na v1.6-mediated persistent current.
    Welch NC; Lin W; Juranka PF; Morris CE; Stys PK
    Neuropharmacology; 2008 Dec; 55(7):1165-71. PubMed ID: 18687344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and in vitro evaluation of 2,4-diamino-1,3,5-triazine derivatives as neuronal voltage-gated sodium channel blockers.
    Ma X; Poon TY; Wong PT; Chui WK
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5644-7. PubMed ID: 19716698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of the action of tolperisone on seven different voltage dependent sodium channel isoforms.
    Hofer D; Lohberger B; Steinecker B; Schmidt K; Quasthoff S; Schreibmayer W
    Eur J Pharmacol; 2006 May; 538(1-3):5-14. PubMed ID: 16650844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: comparison with the Na+ channel-mediated release.
    Sitges M; Guarneros A; Nekrassov V
    Neuropharmacology; 2007 Dec; 53(7):854-62. PubMed ID: 17904592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuroprotective effect of sodium channel blockers in ischemia: the pathomechanism of early ischemic dysfunction].
    Adám-Vizi V
    Orv Hetil; 2000 Jun; 141(23):1279-86. PubMed ID: 10905082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels.
    Kuo CC
    Mol Pharmacol; 1998 Oct; 54(4):712-21. PubMed ID: 9765515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and pharmacological evaluation of conformationally constrained analogues of N,N'-diaryl- and N-aryl-N-aralkylguanidines as potent inhibitors of neuronal Na+ channels.
    Maillard MC; Perlman ME; Amitay O; Baxter D; Berlove D; Connaughton S; Fischer JB; Guo JQ; Hu LY; McBurney RN; Nagy PI; Subbarao K; Yost EA; Zhang L; Durant GJ
    J Med Chem; 1998 Jul; 41(16):3048-61. PubMed ID: 9685245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological modulation of voltage-gated Na+ channels: a rational and effective strategy against ischemic brain damage.
    Urenjak J; Obrenovitch TP
    Pharmacol Rev; 1996 Mar; 48(1):21-67. PubMed ID: 8685246
    [No Abstract]   [Full Text] [Related]  

  • 12. Functional and evolutionary consequences of pyrethroid resistance mutations in S6 transmembrane segments of a voltage-gated sodium channel.
    Zhao Y; Park Y; Adams ME
    Biochem Biophys Res Commun; 2000 Nov; 278(3):516-21. PubMed ID: 11095943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting voltage-gated sodium channels for pain therapy.
    Clare JJ
    Expert Opin Investig Drugs; 2010 Jan; 19(1):45-62. PubMed ID: 20001554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes.
    Sitges M; Galván E; Nekrassov V
    Neurochem Int; 2005 Jun; 46(7):533-40. PubMed ID: 15843047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroreceptors and ion channels as the basis for drug action: past, present, and future.
    Narahashi T
    J Pharmacol Exp Ther; 2000 Jul; 294(1):1-26. PubMed ID: 10871290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]glutamate in hippocampal nerve endings.
    Sitges M; Chiu LM; Guarneros A; Nekrassov V
    Neuropharmacology; 2007 Feb; 52(2):598-605. PubMed ID: 17070874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicinal chemistry of neuronal voltage-gated sodium channel blockers.
    Anger T; Madge DJ; Mulla M; Riddall D
    J Med Chem; 2001 Jan; 44(2):115-37. PubMed ID: 11170622
    [No Abstract]   [Full Text] [Related]  

  • 19. Blockers of voltage-gated sodium channels for the treatment of central nervous system diseases.
    Tarnawa I; Bölcskei H; Kocsis P
    Recent Pat CNS Drug Discov; 2007 Jan; 2(1):57-78. PubMed ID: 18221218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Na+ channels as targets for neuroprotective drugs.
    Taylor CP; Meldrum BS
    Trends Pharmacol Sci; 1995 Sep; 16(9):309-16. PubMed ID: 7482996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.